Muutke küpsiste eelistusi

Textbook of Ocular Pharmacology 3rd Revised edition [Kõva köide]

Edited by , Edited by , Edited by , Edited by , Edited by (Chief of Glaucoma, Department of Ophthalmology, Edith Wolfson Hospital, Tel-Aviv University, Israel)
  • Formaat: Hardback, 800 pages, kõrgus x laius: 279x216 mm, kaal: 2450 g, 41 halftones, 131 line illustrations, 114 tables
  • Ilmumisaeg: 01-Jul-1997
  • Kirjastus: Lippincott Williams and Wilkins
  • ISBN-10: 0781703069
  • ISBN-13: 9780781703062
Teised raamatud teemal:
  • Kõva köide
  • Hind: 204,40 €*
  • * saadame teile pakkumise kasutatud raamatule, mille hind võib erineda kodulehel olevast hinnast
  • See raamat on trükist otsas, kuid me saadame teile pakkumise kasutatud raamatule.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Lisa soovinimekirja
  • Formaat: Hardback, 800 pages, kõrgus x laius: 279x216 mm, kaal: 2450 g, 41 halftones, 131 line illustrations, 114 tables
  • Ilmumisaeg: 01-Jul-1997
  • Kirjastus: Lippincott Williams and Wilkins
  • ISBN-10: 0781703069
  • ISBN-13: 9780781703062
Teised raamatud teemal:
This reference, highlighting breakthroughs in ocular pharmacology, presents information on disease, pathogenesis and pharmacological treatment of a wide range of ocular conditions. It provides an introduction to general concepts of drug action in molecular pharmacology, clinical pharmacology, toxicology and variations in response to drugs. Parasympathetic and symphathetic drug treatment for glaucoma and the development of new drugs for glaucoma are also discussed. The book examines drugs used for the treatment of retinal diseases, cornea and external diseases and provides reviews of common perianaesthetic medications and anaesthetics for ophthalmic surgery. Discussion is also provided of cycloplegics and drug therapy for ophthalmic surgery, as well as the uses of specific diagnostic drugs and of miscellaneous drugs. Finally, the book looks at conditions peculiar to the paediatric patient and their treatment, as well as issues such as toxicology, ocular side effects of drugs, drug interactions, prescription writing and generic drugs.
Section Editors xiii(4) Contributing Authors xvii(10) Preface xxvii(2) Acknowledgments xxix Section I: General Ocular Pharmacology 1(216) Overview 1(2) Mordechai Sharir
1. The History of Ocular Pharmacology 3(6) Mordechai Sharir
2. Pharmacodynamics: Drug-Receptor Interactions 9(26) Frederick W. Benz
3. Drug Reactions Not Mediated via Receptors 35(6) Anat Loewenstein Moshe Lazar
4. Cholinergics 41(10) Craig E. Crosson
5. Eicosanoid Receptors in Ocular Tissues 51(10) Parimal Bhattacherjee
6. Steroids in Ocular Therapy 61(14) Prasad S. Kulkarni
7. Adrenergic Pharmacology of the Anterior Segment 75(20) David E. Potter Gary D. Novack
8. Immunosuppressive Therapy for Uveitis 95(24) Margaret K. L. Cheung James T. Rosenbaum
9. Ocular Pharmacokinetics 119(20) Ronald D. Schoenwald
10. Basic Considerations of Ocular Drug-Delivery Systems 139(12) Amir Bar-Ilan Ron Neumann
11. Development of New Drugs for Ophthalmology 151(14) Gary D. Novack
12. Ethical Issues in Ophthalmic Research 165(6) Mark P. Nasisse
13. The Ophthalmologist as Clinical Investigator 171(8) Gary D. Novack
14. Introduction to Toxicology 179(8) Harrell E. Hurst
15. Effect of Disease on Drug Disposition 187(10) Bruce A. Mueller Steven R. Abel
16. Effect of Age on Drug Disposition 197(8) William F. Buss Steven R. Abel Bruce A. Mueller
17. Effect of Pregnancy on Drug Disposition 205(12) Helen Y. How Joseph A. Spinnato Section II: Glaucoma 217(144) Overview 217(2) Karanjit S. Kooner Thom J. Zimmerman
18. Definitions and Classification of Glaucoma 219(2) Robert D. Fechtner Karanjit S. Kooner
19. Direct, Indirect, and Dual-Action Parasympathetic Drugs 221(18) Paul L. Kaufman BAnn True Gabelt
20. Epinephrine and Dipivefrin 239(8) Ervin N. Fang Michael A. Kass
21. Alpha-2 Agonists in Glaucoma Therapy 247(8) Mark S. Juzych Alan L. Robin Gary D. Novack
22. Thymoxamine (Alpha-Adrenergic Antagonist) 255(6) Karanjit S. Kooner
23. Beta-blockers 261(16) Mark S. Juzych Thom J. Zimmerman
24. Oral Carbonic Anhydrase Inhibitors 277(10) Jeffrey G. Piper
25. Topical Carbonic Anhydrase Inhibitors 287(4) Mordechai Sharir
26. Hyperosmotic Agents 291(6) Kuldev Singh Theodore Krupin
27. Antifibrosis Agents: Pharmacologic Inhibition of Wound Healing 297(18) Bruce C. Henderson George F. Nardin
28. Prostaglandins and Prostaglandin Analogues 315(14) Carl B. Camras Laszlo Z. Bito Carol B. Toris
29. Future Role of Neuroprotective Agents in Glaucoma 329(12) Ozlem Evrem Abbasoglu Karanjit S. Kooner
30. Medical Trabeculocanulotomy 341(6) R. Rand Allingham
31. Physiologic Aspects of Glaucoma and Its Current and Future Management 347(14) Laszlo Z. Bito Section III: Retina 361(110) Overview 361(2) David V. Weinberg Lee M. Jampol
32. Antibiotics and Antifungals 363(24) Travis A. Meredith
33. Antivirals in the Treatment of Retinal Diseases 387(22) Ramana S. Moorthy David V. Weinberg
34. Pharmacologic Therapy for Cystoid Macular Edema 409(8) Lee M. Jampol
35. Proliferative Vitreoretinopathy: Biology and Pharmacology 417(12) Glenn J. Jaffe P. Andrew Pearson
36. Drugs Affecting the Coagulation/Fibrinolysis Pathways 429(14) George A. Williams
37. Ocular Pharmacology of Diabetic Retinopathy 443(4) Lawrence I. Rand
38. Medical Therapy for Macular Degeneration 447(8) Johanna M. Seddon Joan W. Miller
39. Angiogenesis and Growth Factors 455(16) Joan W. Miller Patricia A. DAmore Section IV: Cornea and External Diseases 471(210) Overview 471(2) George R. John Herbert E. Kaufman
40. Penicillins and Cephalosporins 473(20) Adam H. Kaufman Jules Baum
41. Antiparasitic Agents 493(14) Lisa D. Kelly
42. The Tetracyclines 507(8) Carol L. Karp Eduardo C. Alfonso
43. Erythromycin, Clarithromycin, and Azithromycin 515(10) Robert E. Leonard II Carol L. Karp Eduardo C. Alfonso
44. Chloramphenicol 525(6) Carol L. Karp Joseph R. Gussler Eduardo C. Alfonso
45. Aminoglycosides in Ophthalmology 531(6) Steven M. Patalano Robert A. Hyndiuk
46. Fluoroquinolones 537(12) Gregory S. H. Ogawa Robert A. Hyndiuk
47. Peptide Antibiotics: Vancomycin, Bacitracin, and Polymyxin B 549(10) Gerard DAversa George A. Stern
48. Rifampin 559(6) W. Craig Fowler James E. Arena Mark J. Iacobucci
49. Amebic Disease of the Eye 565(10) Hassan Alizadeh Jerry Niederkorn James P. McCulley
50. Antivirals 575(12) James M. Hill Richard J. OCallaghan Bryan M. Gebhardt
51. Pharmacotherapy of Fungus Infections of the Eye 587(22) Terrence P. OBrien Peter Rhee
52. Antiallergic Therapies 609(26) Mark B. Abelson Paula J. McGarr Kevin P. Richard
53. Intraocular Irrigating Solutions 635(20) Henry F. Edelhauser Roger Amass Richard Lambert
54. Surgical Viscoelastic Substances 655(6) Gavin J. Roberts Robert A. Hyndiuk
55. Antiseptics and Disinfectants 661(6) Rajesh K. Rajpal Stephen R. Glaser
56. Mitomycin Treatment of Corneal Disease 667(4) Roswell R. Pfister
57. Cyanoacrylate Tissue Adhesives 671(4) George R. John
58. Future Developments in Corneal Therapy: Growth Factors 675(6) Gregory Schultz Section V: Uveitis 681(82) Overview 681(2) C. Stephen Foster Albert Vitale
59. Pharmacology of Medical Therapy for Uveitis 683(20) Albert Vitale C. Stephen Foster
60. Mydriatic and Cycloplegic Agents 703(10) Albert Vitale C. Stephen Foster
61. Nonsteroidal Antiinflammatory Drugs 713(10) Albert Vitale C. Stephen Foster
62. Immunosuppressive Chemotherapy 723(40) Albert Vitale C. Stephen Foster Section VI: Anesthesia 763(18) Overview 763(2) Martin A. Acquadro
63. Anesthetic and Perianesthetic Medications 765(6) Martin A. Acquadro
64. Anesthetic Considerations for Ophthalmic Surgery 771(10) Martin A. Acquadro Section VII: Ocular Medications for Pediatric Patients 781(24) Overview 781(2) Forrest D. Ellis
65. Topical Ophthalmic Preparations Used for Infants and Children 783(4) Forrest D. Ellis
66. Cycloplegic Agents 787(4) Forrest D. Ellis
67. Topical and Local Anesthetic Agents 791(4) Forrest D. Ellis
68. Antiglaucoma Medications 795(6) Forrest D. Ellis
69. Ocular Antiinflammatory Agents 801(4) Forrest D. Ellis Section VIII: Diagnostic Drugs 805(60) Overview by Carol F. Zimmerman 805(2)
70. Mydriatic and Cycloplegic Drugs 807(20) Carol F. Zimmerman R. Nick Hogan Trang Diem Le
71. Drugs for the Diagnosis of Pupillary Disorders 827(10) Carol F. Zimmerman
72. Drugs for the Diagnosis and Treatment of Myasthenia Gravis 837(12) Gil I. Wolfe Richard J. Barohn Steven L. Galetta
73. Sodium Fluorescein and Other Tissue Dyes 849(16) R. Nick Hogan Carol F. Zimmerman Subject Index 865